GSK has fully
exited its stake in
Haleon, selling the last of its shares for £1.25 billion. Meanwhile
Pfizer also is downscaling its affiliation with the company, planning a £2 billion share sale to reduce its stake from 32% to 24%. Despite these actions,
Haleon's shares appear to be still alluring for some investors, with Optiver Holding B.V. increasing its position, and the company's
CFO acquiring further shares via a dividend. Haleon's Q1 2024 earnings have also shown solid growth, with the company reportedly accelerating its revenue growth at the end of last year. Haleon has also confirmed a major share
buyback, and said to be planning the end of a share price correction. However, there are concerns with a decision to close a UK production site and cut 435 jobs, and with reports of declining revenues. In spite of these challenges, Haleon maintains a positive outlook, leveraging on brand investment and debt reduction.
Haleon Stocks News Analytics from Thu, 05 Oct 2023 07:00:00 GMT to Sat, 08 Jun 2024 10:28:27 GMT -
Rating 1
- Innovation -3
- Information 7
- Rumor 3
